EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia

Vaibhav Agrawal iD, Lindsey Murphy iD, Hoda Pourhassan iD, Vinod Pullarkat iD, Ibrahim Aldoss

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14109 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Vaibhav Agrawal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duar…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Burkitt Lymphoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T‐cell (CAR‐T) therapy has demonstrated unprecedented success in the treatment of various hematologic malignancies including relapsed or refractory (R/R) B‐cell acute lymphoblastic leukemia (B‐ALL). Currently, there are two FDA‐approved CD19‐directed CAR‐T cell products for the treatment of adults with R/R B‐ALL. Despite high remission rates following CD19 CAR‐T cell therapy in R/R B‐ALL, remission durability remains limited in most adult patients, with relapse observed frequently in the absence of additional consolidation therapy. Furthermore, the burden of CAR‐T cell toxicity remains significant in adults with R/R B‐ALL and further limits the wide utilization of this effective therapy. In this review, we discuss patient and disease factors that are linked to CAR‐T cell therapy outcomes in R/R B‐ALL and strategies to optimize durability of response to reduce relapse and mitigate toxicity in the adult population. We additionally discuss future approaches being explored to maximize the benefit of CAR‐T in adults with B‐ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaBurkitt LymphomaAdultHumansImmunotherapy, AdoptiveAntigens, CD19RecurrenceCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

ALLCD19acute lymphoblastic leukemiachimeric antigen receptor

Substanzen

Receptors, Chimeric AntigenAntigens, CD19

Autor:innen und Institutionen

  • Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, California, USA.
  • Department of Pediatrics, City of Hope National Medical Center, Duarte, California, USA.

ORCID-Profile: Vaibhav Agrawal, Lindsey Murphy, Hoda Pourhassan, Vinod Pullarkat

Zitieren

APA

Agrawal, V., Murphy, L., Pourhassan, H., Pullarkat, V., & Aldoss, I. (2024). Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia. European Journal of Haematology. https://doi.org/10.1111/ejh.14109

Vancouver

Agrawal V, Murphy L, Pourhassan H, Pullarkat V, Aldoss I. Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia. European Journal of Haematology. 2024. doi:10.1111/ejh.14109

BibTeX
@article{Agrawal2024,
  author = {Agrawal, Vaibhav and Murphy, Lindsey and Pourhassan, Hoda and Pullarkat, Vinod and Aldoss, Ibrahim},
  title = {Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14109}
}
Kostenlos starten →